These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23528218)

  • 1. Vemurafenib: an unusual UVA-induced photosensitivity.
    Gelot P; Dutartre H; Khammari A; Boisrobert A; Schmitt C; Deybach JC; Nguyen JM; Seité S; Dréno B
    Exp Dermatol; 2013 Apr; 22(4):297-8. PubMed ID: 23528218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phototoxicity of B-RAF inhibitors: Exclusively due to UVA radiation and rapidly regressive.
    Gabeff R; Dutartre H; Khammari A; Boisrobert A; Nguyen JM; Quereux G; Brocard A; Saint-Jean M; Peuvrel L; Dreno B
    Eur J Dermatol; 2015; 25(5):452-6. PubMed ID: 26242321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.
    Brugière C; Stefan A; Morice C; Cornet E; Moreau A; Allouche S; Verneuil L
    Br J Dermatol; 2014 Dec; 171(6):1529-32. PubMed ID: 25066094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The phototoxicity of vemurafenib: An investigation of clinical monochromator phototesting and in vitro phototoxicity testing.
    Woods JA; Ferguson JS; Kalra S; Degabriele A; Gardner J; Logan P; Ferguson J
    J Photochem Photobiol B; 2015 Oct; 151():233-8. PubMed ID: 26318280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of vemurafenib phototoxicity in a mouse model.
    Boudon SM; Plappert-Helbig U; Odermatt A; Bauer D
    Toxicol Sci; 2014 Jan; 137(1):259-67. PubMed ID: 24154489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
    Boudewijns S; Gerritsen WR; Koornstra RH
    BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.
    Brown MP; Long GV
    Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl S3():1-15. PubMed ID: 24712861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.
    Anforth R; Carlos G; Eiris N; Clements A; Fernandez-Peñas P
    Med J Aust; 2015 Jul; 203(1):41-2. PubMed ID: 26126567
    [No Abstract]   [Full Text] [Related]  

  • 13. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultraviolet A and photosensitivity during vemurafenib therapy.
    Dummer R; Rinderknecht J; Goldinger SM
    N Engl J Med; 2012 Feb; 366(5):480-1. PubMed ID: 22296092
    [No Abstract]   [Full Text] [Related]  

  • 17. Vemurafenib in melanoma.
    Shaw HM; Nathan PD
    Expert Rev Anticancer Ther; 2013 May; 13(5):513-22. PubMed ID: 23617343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma.
    Guerreschi P; Scalbert C; Qassemyar A; Kluza J; Ravasi L; Huglo D; Martinot-Duquennoy V; Formstecher P; Marchetti P; Mortier L
    Melanoma Res; 2013 Oct; 23(5):373-80. PubMed ID: 23852164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abrupt development of Dupuytren's contractures with the BRAF inhibitor vemurafenib.
    Sibaud V; Chevreau C
    Joint Bone Spine; 2014 Jul; 81(4):373-4. PubMed ID: 24468667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.